Equities

Insmed Inc

Insmed Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)73.84
  • Today's Change0.025 / 0.03%
  • Shares traded363.17k
  • 1 Year change+211.15%
  • Beta1.0998
Data delayed at least 15 minutes, as of Nov 22 2024 17:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform13
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 17 analysts offering 12 month price targets for Insmed Inc have a median target of 88.00, with a high estimate of 105.00 and a low estimate of 74.00. The median estimate represents a 19.23% increase from the last price of 73.81.
High42.3%105.00
Med19.2%88.00
Low0.3%74.00

Earnings history & estimates in USD

On Oct 31, 2024, Insmed Inc reported 3rd quarter 2024 losses of -1.27 per share. This result was in line with the consensus of the 15 analysts following the company and under-performed last year's 3rd quarter results by 14.41%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-11.65%
Insmed Inc reported annual 2023 losses of -5.34 per share on Feb 22, 2024.
Average growth rate-16.56%
More ▼

Revenue history & estimates in USD

Insmed Incorporated had 3rd quarter 2024 revenues of 93.43m. This bettered the 93.01m consensus of the 13 analysts covering the company. This was 43.26% above the prior year's 3rd quarter results.
Average growth rate+4.78%
Insmed Incorporated had revenues for the full year 2023 of 305.21m. This was 24.39% above the prior year's results.
Average growth rate+22.42%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.